Business Wire

CA-VELODYNE-LIDAR,-INC.

15.11.2018 14:02:11 CET | Business Wire | Press release

Share
Automotive Innovator, Rick Tewell, Promoted to Chief Operating Officer at Velodyne Lidar

Velodyne Lidar, Inc. announces the promotion of Rick Tewell to Chief Operating Officer. Tewell assumes leadership of the company’s vast manufacturing efforts at its Megafactory in San Jose, California. He joined the company in September 2017 as Senior Vice President of Automated Manufacturing and was promoted to Chief Advanced Manufacturing Officer prior to the promotion to COO. He brings a wealth of expertise to the day-to-day production of Velodyne’s industry-leading lidar sensor product line.

This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20181115005168/en/

According to Marta Hall, Velodyne’s President and Chief Business Development Officer, Velodyne “recruited Rick Tewell to manage Robotics and Advanced Technology, and within a year it was clear he could lead Operations as COO. Velodyne Lidar is at the extreme edge of high tech, and Rick meets the challenge with da Vinci-like multiple talents. In the last three months Rick upgraded the entire Velodyne Megafactory with robotics and newly designed innovative processes for production. As COO he brings a futuristic vision and fresh energy to the operations of the company.”

“My main responsibility,” said Tewell, “is to take a design that came from the mind of a genius, David Hall [Velodyne’s Founder and CEO], and make it into a product worthy of the Velodyne name. I work with David and Anand [Gopalan, Velodyne’s Chief Technology Officer] to translate these wonderful designs that have the ability to change the world into something that is manufacturable and then ramp production to meet the demand. To take an invention from Dave Hall and turn it into a manufacturable product is a huge responsibility and one that I take very seriously. It’s an incredible opportunity. I get out of bed excited to go to work, and I go to bed thinking about it.”

According to Tewell, the job of Chief Operating Officer at Velodyne is unlike any other. Between designing and manufacturing the highest quality sensors on the market comes the equally challenging task of inventing and building the machines that then build the sensors.

“For our sensors to be able to see so far and produce incredibly accurate data for autonomous vehicles to use, we have to employ incredibly precise processes, which include utilizing robotics and automation. So we need to also invent the machines that will build our sensors.” Given the uniqueness of Velodyne’s products, Tewell pointed out that he must address the complex processes of “taking something that’s never been invented or built before and building tens of thousands -- hundreds of thousands -- millions of them. It is a whole series of inventions to produce the sensor invention. So, it is not just the genius of the lidar itself; it’s the genius of saying, ‘This is what you are going to need to invent in order to manufacture the sensor.’”

Before coming to Velodyne, Tewell established a successful career in the automotive semiconductor industry, including stops at Fujitsu and NVIDIA. Rick remembers, “The idea that cars eventually would be robots emerged while Dave Hall was participating in the DARPA Grand Challenge. At NVIDIA we were creating the brains that would be used in self-driving cars.” Tewell’s interest and experience in developing key technologies for autonomous mobility grew over the years. Finally, Tewell decided to join Velodyne with the clear realization that he would be “aligning with a company that will be one of, if not the, principal company in the self-driving industry.”

Tewell recognizes the essential role Velodyne’s products have in enabling safe mobility at scale. “We are working hard to meet the next wave of demand for sensors to put on autonomous vehicles. Scaling up will drive the cost down to where the price is attractive to all customers. But we will never compromise on quality. It is critical from an operations standpoint that our product will ultimately impact someone’s life. This realization needs to permeate every aspect of what we do. This is not a piece of technology that is going to stay in a box. When you put a sensor on a car the person in that car is trusting that technology to keep them safe.”

About Velodyne Lidar

Founded in 1983 and headquartered in Silicon Valley, Velodyne is a technology company known worldwide for its real-time 3D lidar computing and software platforms. The company evolved after founder David Hall invented the HDL-64 Solid-State Hybrid lidar sensor in 2005. Since then, Velodyne Lidar, Inc. emerged as the unmatched market leader of real-time 3D vision systems used in a variety of commercial applications including autonomous vehicles, vehicle safety systems, mobile mapping, aerial mapping, and security. Its products range from the high-performance, surround view Ultra-Puck™ VLP-32, classic HDL-32/64 and cost-effective VLP-16, the new VLS-128, to the upcoming, hidden Velarray™. Velodyne’s rich suite of perception software and algorithms are the key enablers of its perception systems. Velodyne supports customers from offices in San Jose, Detroit, Frankfurt, and Beijing. For more information, visit http://www.velodynelidar.com .

Contact:

David Cumpston Landis Communications for Velodyne Lidar, Inc. (415) 359-2316 velodyne@landispr.com

Social Media:

https://www.facebook.com/velodyneLiDAR/

About Business Wire

Business Wire
Business Wire
101 California Street, 20th Floor
CA 94111 San Francisco

http://businesswire.com

Subscribe to releases from Business Wire

Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.

Latest releases from Business Wire

International Human Rights Lawyer Jared Genser and Former White House Counsel Lanny J. Davis Join Legal and Advocacy Team Supporting Cambodian Businessman Yim Leak, Seiden Law LLP Announces18.9.2026 19:52:00 CEST | Press release

Jared Genser, one of the world's most recognized international human rights lawyers, and Lanny J. Davis, an adviser to former presidents George W. Bush and Bill Clinton, join the legal and advocacy team for Cambodian businessman Yim Leak and challenge what they call a coordinated smear campaign in Thailand. International human rights lawyer Jared Genser and Lanny J. Davis, who has close ties to two former US presidents and a worldwide reputation for defending those under attack with lies and smears, and for repairing the damage done to their reputations, have joined the legal and advocacy team supporting Cambodian businessman Yim Leak, Seiden Law LLP, which serves as Yim Leak's chief global counsel, announced today. Their first move is to hold the Thai government accountable, framing its conduct as either complicit in or willfully blind to a sustained smear campaign against Yim. Genser is Managing Director of Perseus Strategies, an international law firm. Over more than two decades, he

Ningbo FEED Meeting Confirms Full Confidence in Q1 2027 FID for Allied Biofuels’ US$6.1 Billion Presidential Decree-Backed SAF and e-SAF Project18.9.2026 17:38:00 CEST | Press release

Allied Biofuels has held a major Front-End Engineering Design (FEED) meeting at Sinopec’s office in Ningbo, China, bringing together Allied Biofuels, Sinopec Engineering Group Co., Ltd. of China, Topsoe A/S of Denmark, Sasol South Africa Limited, and Plug Power of the United States — the principal international engineering and technology providers supporting its US$6.1 billion Presidential Decree-backed Sustainable Aviation Fuel (SAF) and e-SAF project in Uzbekistan. This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20260918708077/en/ FEED Meeting - Ningbo, China At the joint FEED meeting of the project’s core engineering and technology stakeholders, the discussions established clear alignment on engineering responsibilities, technology interfaces, design deliverables, project integration and the coordinated execution programme required to advance the project through FEED. All stakeholders working on the project expressed full co

Corcept Announces CHMP Opinion Recommending EU Marketing Authorization for Lifyorli® (Relacorilant)18.9.2026 14:00:00 CEST | Press release

Corcept Therapeutics Incorporated (NASDAQ: CORT), a commercial-stage company engaged in the discovery and development of medications to treat severe endocrinologic, oncologic, metabolic and neurologic disorders by modulating the effects of the hormone cortisol, today announced that the European Medicines Agency’s Committee for Medicinal Products for Human Use (CHMP) has recommended that the European Commission (EC) should approve relacorilant, combined with the chemotherapy drug nab-paclitaxel, for the treatment of patients with platinum-resistant ovarian cancer. The CHMP’s recommendation is based on positive data from Corcept’s Phase 2 and pivotal Phase 3 ROSELLA trials, in which patients receiving relacorilant combined with nab-paclitaxel experienced improved progression-free and overall survival compared to patients who received nab-paclitaxel alone. The safety profile of relacorilant plus nab-paclitaxel in these trials was consistent with the safety profile of nab-paclitaxel monoth

Enhertu® Recommended for Approval in the EU by CHMP as Adjuvant Treatment for Patients with Residual Disease After Neoadjuvant Treatment for HER2 Positive Early Breast Cancer18.9.2026 14:00:00 CEST | Press release

Recommendation based on DESTINY-Breast05 phase 3 trial results that showed Enhertu reduced the risk of invasive disease recurrence or death by 53% versus T-DM1 Daiichi Sankyo and AstraZeneca’s Enhertu has the potential to become a new standard of care in this early breast cancer setting Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the adjuvant treatment of adult patients with resected HER2 positive breast cancer who have residual invasive disease after neoadjuvant taxane-based and HER2 targeted treatment. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from the DESTINY-Breast05 phase 3 trial presented at th

CHMP Recommends EU Approval of New Indication for Alfasigma’s Jyseleca® (filgotinib), Treatment of Adults With Axial Spondyloarthritis18.9.2026 12:58:00 CEST | Press release

The information contained within this press release is for the purpose of scientific exchange.It is intended for scientific, financial and investor media only.If approved, Jyselecawill be indicated for the treatment of patients with active axial spondyloarthritis (axSpA), both non-radiographic and radiographic forms of the disease, who have responded inadequately to conventional therapy.Despite the availability of multiple treatment options, nearly half of people living with axSpA do not respond adequately to current therapies, and just 10-20% reach inactive disease within 16-24 weeks of initiating treatment.CHMP’s positive opinion is based on findings from the OLINGUITO Phase 3 study, where improvements in the signs and symptoms of axSpA with filgotinib were observed early and maintained over 52 weeks of treatment.Jyselecais already approved in Europe and the United Kingdom, for the treatment of moderate to severe rheumatoid arthritis and ulcerative colitis. Alfasigma S.p.A, a global

In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.

Visit our pressroom
World GlobeA line styled icon from Orion Icon Library.HiddenA line styled icon from Orion Icon Library.Eye